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Abstract: High-density lipoprotein cholesterol (HDL-C) concentration is essential in the 
determination of coronary heart disease (CHD) risk in women. This is especially true in the 
postmenopausal state, where lipid profiles and CHD risk mimic that of age-matched men. 
Thus, interventions designed to reduce CHD risk by raising HDL-C levels may have particular 
significance during the transition to menopause. This review discusses HDL-C-raising therapies 
and the role of HDL in the primary prevention of CHD in women. Lifestyle-based interventions 
such as dietary change, aerobic exercise regimens, and smoking cessation are initial steps that 
are effective in raising HDL-C, and available data suggest women respond similarly to men 
with these interventions. When combined with pharmacotherapy, the effects of these lifestyle 
alterations are further amplified. Though studies demonstrating gender-specific differences in 
therapy are limited, niacin continues to be the most effective agent in raising HDL-C levels, 
especially when used in combination with fibrate or statin therapy. Emerging treatments such 
as HDL mimetic therapy show much promise in further raising HDL-C levels and improving 
cardiovascular outcomes.
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Introduction
Coronary heart disease (CHD) remains the leading cause of death in American women 
and is responsible for more deaths in women than all forms of cancer combined. CHD 
now ranks first among all disease categories in hospital discharge diagnoses for women, 
and it continues to pose a greater diagnostic challenge in women than men.1
The assessment of CHD risk and its subsequent management relies heavily on 
lipid and lipoprotein levels. HMG-CoA reductase inhibitor (statin) therapy, aimed 
primarily at decreasing low-density lipoprotein cholesterol (LDL-C) levels, remains 
at the forefront in primary and secondary CHD prevention in both sexes. However, 
approximately 65% to 75% of cardiovascular events still occur despite statin use.2 
There is a great need for other target therapies, most notably high-density lipoprotein 
cholesterol (HDL-C) raising strategies, to further prevent CHD.
In several studies, HDL-C concentration was found to be the best predictor of 
coronary heart disease risk in women.3–5 The Framingham Heart Study showed women 
in the lowest quintile of HDL-C to have a relative risk of CHD three times higher than 
those in the highest quintile.6 The current body of literature, however, is limited with 
regard to HDL-C-raising therapies specifically for women.
This review discusses the mechanisms by which HDL exerts its favorable 
cardiovascular effects and examines the role HDL plays in the primary prevention International Journal of Women’s Health 2009:1 182
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of CHD in women. Moreover, HDL-C concentration will 
be explored as a therapeutic target as current, as well as 
emerging, HDL-C-raising therapies in women are evaluated. 
We reviewed recent and past literature using Ovid Medline 
and PubMed databases (National Library of Medicine, 
Bethesda, MD, USA) from 1955 to present. Search terms 
used included HDL, cholesterol, lipids, metabolism, 
pathogenesis, women, gender, sex, coronary heart disease, 
exercise, and estrogen.
HDL metabolism
The mature HDL particle is comprised of a cholesterol core 
surrounded by an outer shell of phospholipids and apolipoproteins. 
Through a mechanism known as reverse cholesterol transport, 
the particle promotes the efflux of surplus cellular cholesterol 
from peripheral tissues and delivers it to the liver for eventual 
excretion in the bile. This “removal” of excess cholesterol from 
cells and lipid-containing macrophages represents much of the 
proposed atheroprotective benefit of HDL.7–9
HDL assembly begins with the secretion of lipid-poor 
apolipoprotein A-I (apoA-I) from the liver and intestine. 
In reverse cholesterol transport, the nascent particle interacts 
with ATP-binding cassette transporter 1 (ABCA1) to acquire 
excess cholesterol from cells and atherosclerotic plaques, 
forming an early HDL particle known as pre-beta-HDL. 
Alternatively, it may acquire cholesterol released from 
lipoprotein lipase-mediated lipolysis of triglyceride-rich 
very low LDL (VLDL) and chylomicrons. Free cholesterol in 
pre-beta-HDL is subsequently esterified by apoA-I-mediated 
activation of the enzyme lecithin-cholesterol acyltransferase 
(LCAT), resulting in the formation of mature alpha-HDL 
particles.8,10
Cholesterol is subsequently transferred to sites such 
as the liver through various mechanisms. In one, HDL-C 
is selectively transported into hepatocytes and cells of 
steroidogenic tissues such as the ovary and the adrenal 
gland via the Scavenger receptor class B, type I (SR-B1).10 
Potential fates for this cholesterol include excretion through 
bile or storage and utilization for purposes such as hormone 
synthesis. Cholesterol may alternately be transferred to other 
lipoprotein particles via lipid transfer proteins such as the 
cholesterol ester transfer protein (CETP), which mediates 
the transfer of cholesterol esters from HDL particles to less 
favorable VLDL, intermediate-density lipoprotein (IDL), and 
LDL particles.11 Inhibition of CETP as a method for raising 
HDL-C will be discussed later in this review.
Aside from its role in reverse cholesterol transport, HDL 
has been shown to exert a variety of other anti-inflammatory 
actions in the laboratory setting. HDL inhibits the rate 
of macrophage-induced oxidation of LDL,12 and it also 
inhibits oxidized LDL-induced upregulation of cell adhesion 
molecules.13 HDL stimulates the synthesis of the eicosanoid 
prostacyclin (PGI2), which in turn inhibits platelet activation 
and vascular smooth muscle cell growth and migration.14 
PGI2 also inhibits endothelial cell apoptosis and decreases 
complement activation.15 Additionally, HDL has been shown to 
increase the expression and activity of endothelial nitric oxide 
synthase (eNOS), thereby potentially exerting favorable effects 
on coronary and peripheral arterial endothelial function.16,17 
Though their applicability outside the laboratory setting 
remains uncertain, these encouraging biologic properties of 
the HDL particle suggest additional antiatherogenic influence 
independent of HDL ’s role in cholesterol mobilization.
Despite its seemingly consistent favorability, HDL is 
relatively heterogenous in makeup. Using proton nuclear 
magnetic resonance (NMR) spectroscopy and vertical 
spin density-gradient ultracentrifugation modalities, HDL 
particles can be classified by density into HDL2 and HDL3 
subfractions. HDL2 is the larger, more buoyant, less dense 
form that is rich in apoA-I, while HDL3 is the smaller, 
denser form that contains both apoA-I and apoA-II.18 While 
the apoA-I-predominant members of the HDL2 subfraction 
appear to be more active in reverse cholesterol transport,19 
data supporting clear differences in cardiovascular risk 
based on HDL subfraction distribution are limited.18,20 
Further investigation is needed before an understanding 
of HDL functionality and particle size can be applied to 
cardiovascular risk assessment.
Relation of HDL-C and CHD  
in women
Low HDL-C levels have been shown to be a risk factor 
for CHD and premature atherosclerosis independent of 
serum LDL-C21 and triglyceride levels.22 In women with 
established coronary disease, low HDL-C levels may be a 
better predictor of subsequent coronary events than high 
levels of LDL-C.5 The Nurses’ Health Study estimates that 
a 17 mg/dL elevation in HDL-C reduces the risk of CHD 
development in postmenopausal women by approximately 
40%.23 In general, the risk of CHD decreases by 3% for every 
1 mg/dL increase in HDL-C in women, but only by 2% in 
men.24 Similarly, the presence of diabetes tends to confer a 
more negative effect on HDL-C and triglycerides (TG) in 
diabetic women compared to men.25
Angiographic and ultrasound evidence demonstrate that 
low plasma levels of HDL-C are associated with greater International Journal of Women’s Health 2009:1 183
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severity of CHD in females and males, as indicated by 
an increase in the number and extent of coronary vessel 
involvement.26 Furthermore, among men and women with 
angiographic evidence of CHD but with normal total 
cholesterol levels, patients with HDL-C levels 35 mg/dL 
had significantly more cardiovascular events than those with 
higher levels.27
The Third Adult Treatment Panel of the National 
Cholesterol Education Panel (NCEP ATP III) broadly 
classified HDL-C levels less than 40 mg/dL as low and 
predictive of cardiovascular risk, while HDL-C levels greater 
than 60 mg/dL were defined as high and deemed protective.28 
Reflecting gender-specific differences in serum HDL-C 
concentrations, however, a more inclusive risk cutpoint 
of 50 mg/dL was established for identifying metabolic 
syndrome in women. Today, this higher HDL-C cutpoint is 
more commonly used when assessing cardiac risk in females, 
given the observed incidence of coronary disease in women 
with comparatively higher HDL-C levels than men.5,29,30 For 
these reasons, any approach to cardiovascular risk assessment 
should always be comprehensive.
Menopause
Prior to menopause, the risk of CHD in women is 2.5 to 
4.5 times lower than that of age-matched men.31 This find-
ing correlates to lower levels of LDL-C and higher levels 
of HDL-C in premenopausal women compared to males of 
similar age. However, within 10 years of menopause, the 
risk of CHD in women increases to a level similar to that in 
men.32 The mechanism for this precipitous rise in cardiac risk 
is likely multifactorial, though alterations in lipid metabolism 
in the face of estrogen deficiency may play a significant role. 
Specifically, reductions in HDL-C levels and elevations in 
total cholesterol, TG, fibrinogen, and lipoprotein (a) levels 
are observed following menopause.33–38
While age may contribute to altered lipid metabolism, 
menopause itself has been shown to have a stronger correlation. 
In a longitudinal study of 541 initially premenopausal women 
aged 42 to 50 years, greater changes in blood lipid levels were 
seen in those women who underwent menopause than in those 
who did not. In fact, those who maintained their premeno-
pausal status during the study period showed no change in 
HDL-C levels.35 These findings support the general consensus 
that menopause, whether surgical or natural, is associated 
with a less desirable lipid profile.2,5,16,21,22,36,39–42
In addition to bringing large absolute reductions in 
HDL-C levels, menopause appears to herald changes in the 
actual composition of HDL particles. The distribution of HDL 
subspecies is altered in menopause, with a reduction seen in 
the proportion of large, buoyant HDL2 particles, which are 
believed to be more active in reverse cholesterol transport.19 
In contrast, smaller, more dense HDL3 subfragments rise.33,43 
Additionally, ex vivo biochemical analysis of lipoproteins 
from pre- and post-menopausal women suggest the 
post-menopausal HDL particle exhibits impaired ability to 
limit LDL oxidation.44 While small trials such as these lack 
true clinical implications, they support the notion that meno-
pause brings with it abnormalities in lipid metabolism that 
transcend simple changes in lipoprotein concentrations.
HDL-C-raising interventions
At the outset, lifestyle change should be recommended 
to all patients with low HDL-C levels. Effective lifestyle-
based interventions include smoking cessation, initiation 
of an aerobic exercise program, weight loss, moderate 
alcohol consumption, and adoption of a low carbohydrate or 
Mediterranean diet.28 A combination of these interventions 
may result in improved HDL-C levels, thereby reducing 
the need for medications. A patient’s CHD risk and her 
starting HDL-C level will determine the need for additional 
pharmacologic intervention.
Diet
Diets high in omega-3 fatty acids have been shown to increase 
HDL-C and decrease TG levels.45–48 Foods rich in omega-3 
include “oily” fish such as tuna, mackerel, sardines, and 
salmon. Nonaquatic food sources include walnuts, green, 
leafy vegetables, flaxseed oil, and certain fortified foods. The 
Mediterranean diet is abundant in omega-3 fatty acids and 
has been shown to reduce serum inflammatory markers and 
raise HDL-C levels, although to a minimal extent.49 Estruch 
et al demonstrated that a Mediterranean diet supplemented 
with virgin olive oil produced a significant 2.3 mg/dL increase 
in HDL-C at three months when compared to a Mediterra-
nean diet with mixed nuts (0.94 mg/dL increase) and a low 
fat diet (0.37 mg/dL decrease). No gender differences were 
observed in the subgroup analysis, and beneficial effects 
on other cardiovascular risk factors, such as fasting plasma 
glucose, systolic blood pressure, and C-reactive protein, 
were further described.50 It should be noted, however, that 
trials of pharmacologic supplementation with omega-3 fatty 
acids have depicted only marginal benefit on HDL-C, despite 
substantial TG-lowering effects.51
Low-carbohydrate diets have also been shown, on 
average, to increase HDL-C levels by 20%.52 In a randomized, 
two-period, crossover study in 10 healthy normolipidemic International Journal of Women’s Health 2009:1 184
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women who consumed both a low fat (30% fat) and 
a very low carbohydrate diet (10% carbohydrate), the 
very low carbohydrate diet increased total cholesterol, 
LDL-C and HDL-C by 16%, 15%, and 33%, respectively.53 
A similar study performed by the same investigators in men 
demonstrated respective increases of 5%, 4%, and 12% after 
a six-week very low carbohydrate diet.54 Conversely, low-fat 
diets typically result in a decrease of all lipoprotein levels, 
including a slight decrease in HDL-C levels.55,56 Controlled-
feeding studies have similarly demonstrated a greater rise in 
HDL-C in women compared to men when diets with lower 
carbohydrate relative to fat are administered, illustrating 
differences in lipoprotein response to diet based on gender.57 
Despite this, clinically-relevant cardiovascular outcomes 
benefits associated with low carbohydrate diets have not been 
described, and as such, dietary moderation may be the most 
prudent recommendation to patients.
Alcohol intake
A substantial body of data has demonstrated the beneficial 
effects of moderate alcohol intake on serum lipids, most 
notably an increase in HDL-C. Gaziano and colleagues 
examined the effects of daily moderate alcohol consumption 
(one to three drinks) in 340 patients (74 women) with 
previous myocardial infarction (MI), compared to an 
equal number of healthy patients without history of MI.58 
Concentrations of HDL-C and both its major subfractions 
were strongly associated with alcohol consumption, and 
an inverse association was demonstrated between alcohol 
consumption and risk of MI. No such relationship was 
apparent for concentrations of total cholesterol, LDL-C, 
VLDL, or TGs. In a nested case control study examining 
the effects of alcohol intake in 249 women and 266 men 
with incident MI compared to similarly matched women and 
men without history of MI, frequency of drinking tended to 
be associated with lower risk of MI. Those with the lowest 
risk drank three to four days per week (with women, on 
average, drinking 18.2 to 20.1 g of alcohol per drinking 
day and men drinking 22.4 and 26.2 g per drinking day). 
Among women, multivariate analysis suggested an odds 
ratio (OR) of 0.76 (95% confidence interval [CI]: 0.59 
to 0.97), which corresponded to a regression (r) coefficient 
of -0.28 per drinking day. HDL-C alone accounted for 36% 
of this association. In men, the OR was 0.86 (95% CI: 0.74 
to 1.0), with r = -0.15. HDL-C accounted for 53% of this 
association.59 These findings suggest a stronger inverse 
relationship of alcohol use in women over men, with HDL-C 
playing a large contributing role.
Moderate alcohol consumption of approximately 30 g 
per day has been shown to increase HDL-C by 4 mg/dL 
and apoA-I by 9 mg/dL, with an overall cardiovascular 
risk reduction of approximately 25%.60 Conversely, 
heavy alcohol consumption negates these effects through 
a variety of mechanisms and confers increased risk of 
CHD and metabolic syndrome.61,62 Progressive fatty acid 
accumulation, hepatic steatosis, and subsequent liver injury 
develop with heavy alcohol intake, mediated in part by 
malnutrition as well as direct cellular and mitochondrial 
toxicity accompanying ethanol oxidation.63,64 The exogenous 
and endogenous secondary hypertriglyceridemia typically 
seen in heavy alcohol consumption is further potentiated 
by increased hepatic VLDL synthesis and impaired removal 
of TG-containing lipoproteins from the circulation. When 
hepatic dysfunction is particularly severe, a paradoxical 
decrease in circulating HDL-C is observed, likely due in 
part to impaired synthesis of apoA-I and apoA-II by the 
dysfunctional liver.65,66
Smoking
Data suggest smoking has a similarly deleterious effect 
upon HDL-C concentration in women and men. A study of 
2,553 women, aged 20–69 years, from 10 North American 
populations revealed that women who smoked 20 or more 
cigarettes/day had 9.4 mg/dL lower HDL-C levels when 
compared to nonsmokers.67 The Framingham Offspring Study 
revealed that active cigarette smoking was associated with an 
average HDL-C decrease of 4 mg/dL in men and 6 mg/dL in 
women. When controlled for heavy alcohol use, a significant 
negative association between number of cigarettes smoked 
and HDL-C was demonstrated in both sexes. Among those 
who had quit smoking for over one year, no difference in 
HDL-C levels was observed when compared to nonsmokers.68 
Furthermore, smoking cessation may increase HDL-C levels 
in as little as two weeks.69
Exercise
Aerobic exercise has proven to be modestly efficacious in 
increasing HDL-C while decreasing total cholesterol, LDL-C, 
and TG in women. In a recent meta-analysis of randomized 
controlled trials conducted between 1955 and 2003 in which 
aerobic exercise was used as the primary intervention in adult 
women 18 years (n = 1022 in exercise group, n = 633 in 
control group), an HDL-C increase of 3% was noted between 
experimental and control groups. No statistically significant 
differences were noted between pre- and post-menopausal 
women, or those who were on pharmacotherapy affecting International Journal of Women’s Health 2009:1 185
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lipids and lipoprotein levels compared to participants who 
were not receiving treatment. A statistically significant and 
positive association was observed however between HDL-C 
and VO2max, with greater increases in HDL-C associated with 
greater increases in VO2max. Furthermore, TC, LDL-C, and 
TG were decreased by 2%, 3%, and 5%, respectively, with 
exercise.70
Body habitus
Alterations in body fat content and distribution occur naturally 
in both males and females with the aging process. Indices of 
body fat distribution and adiponectin have been demonstrated 
to correlate with insulin resistance in older women. The effect 
of weight loss on HDL-C levels, however, is unclear. Some 
studies in women suggest an initial decline in HDL-C with 
weight loss,71 while other data suggest the manner of weight 
loss matters more. While low-carbohydrate, high-fat diets 
may improve serum HDL-C, high-carbohydrate, low-fat 
diets tend to have fewer unwanted effects on LDL-C.72,73 
Again, avoidance of diet extremes should be emphasized 
during weight loss.
Compared to men, women are prone to a greater 
frequency of HDL-C variations throughout life. Azogui and 
colleagues found that sex steroid hormone fluctuations during 
the menstrual cycle affect levels of serum lipoproteins and 
their constituents, particularly HDL-C. HDL-C was found 
to increase by 16% in the preovulatory phase, in comparison 
to the early follicular phase. Serum apolipoprotein A-I was 
elevated in the preovulatory (a 14% increase) and mid-luteal 
phase (a 19% increase) in comparison to the early follicular 
phase. In the mid-luteal phase, the apoA-I/HDL-C ratio was 
higher than in the other two phases, suggesting altered HDL 
composition during this phase. These findings suggest that 
endogenous progesterone, unlike some synthetic progestins, 
does not negate the beneficial effect of estrogen on serum 
HDL-C levels. Concentrations of other lipoproteins, 
including TC, TG, VLDL-C, LDL-C, and apolipoprotein-B, 
did not change throughout the cycle.74
Adverse alterations in the lipid profile have also been 
described during and after pregnancy. Additionally, pregnancy 
frequency, including frequency of spontaneous abortion, and 
age at first pregnancy have been associated with increased 
coronary disease risk.75–77 Analysis of data from the Coronary 
Artery Risk Development in Young Adults (CARDIA) study, 
revealed that two-year change in HDL-C was significantly 
different among parity groups. HDL-C levels significantly 
decreased in women who had their first pregnancy of at least 
28 weeks duration during follow up (-3.5 ± 1.2 mg/dL), 
versus an increase in HDL-C in those women parous at 
baseline who had no further pregnancies (2.5 ± 0.3 mg/dL) 
and in nulliparous women (2.4 ± 0.3 mg/dL). Differences 
in HDL-C levels remained significant after controlling for 
factors such as age, oral contraceptive use, changes in body 
mass index (BMI), waist-to-hip ratio, smoking and alcohol 
status, while no differences were observed in concentrations 
of LDL-C or TG.8 Other longitudinal78,79 and cross-sectional 
studies80,81 have shown similar inverse associations between 
multiparity and levels of HDL-C.
Pharmacotherapy
Medications have proven to be the easiest and most efficacious 
way to increase HDL-C levels. Combined with lifestyle-based 
interventions, medication effects are further amplified. 
In patients with established CHD, current guidelines 
recommend intensive lifestyle modification combined with 
statin-based pharmacotherapy to bring LDL-C levels to goal 
before HDL-C titration is attempted. There is no evidence that 
pharmacotherapy is necessary for primary CHD prevention 
in women at low to intermediate risk.28,82–84
Statins
HMG-CoA-reductase inhibitors, also known as statins, are 
a staple in the lipid lowering armamentarium and are used 
primarily to reduce LDL-C. They also have the added benefit 
of raising HDL-C levels, typically by 5%–15%. Statins 
work by inhibiting the biosynthesis of hepatic cholesterol, 
upregulating the expression of hepatic LDL receptors, and 
stimulating hepatic production of apoA-I.85
The Air Force/Texas Coronary Atherosclerosis Prevention 
Study (AFCAPS/TexCaps), a primary prevention trial com-
paring lovastatin to placebo in 997 postmenopausal women 
and 5,608 men with average LDL-C levels, below average 
HDL-C levels and no evidence of CHD, demonstrated a 25% 
reduction in LDL-C levels and a 9% increase in HDL-C levels 
in postmenopausal women in the treatment group, though 
significant differences in lipid effects between genders were 
not described.86 The Greek Atorvastatin and Coronary heart 
disease Evaluation (GREACE) Study, a secondary prevention 
trial in 1,600 patients, 22% of whom were women, with 
known CHD described a similar 7% increase in HDL-C levels 
with atorvastatin, though increases appeared proportionally 
greater in men (7.8 vs 6.1%; P = 0.02).87
High-dose rosuvastatin at 40 mg/d produced an even 
greater 14.7% increase in HDL-C in women and men while 
inducing regression of atheromatous plaques in a 2006 study 
utilizing intravascular ultrasound (IVUS).88 Statins also International Journal of Women’s Health 2009:1 186
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appear to provide the greatest angiographic and clinical 
benefit in patients with low HDL-C levels, as was evidenced 
in the Lipoprotein and Coronary Atherosclerosis Study.89 
Changes in HDL-C with statin therapy, although modest, 
may contribute to additional cardiovascular risk reduction 
independent of LDL-C.90
Fibrates
Unlike their effects on serum TG, fibrates appear to be more 
modest in raising HDL-C, in the range of 10%–15%.91,92 Fibric 
acid derivatives exert their biochemical effect by activating the 
peroxisome proliferator-activated receptors (PPARs) family 
of nuclear transcription factors. Fibrate-mediated activation 
of PPAR-alpha, in particular, induces synthesis of the primary 
HDL apolipoproteins, apoA-I and apoA-II. Additionally, 
fibrates upregulate lipoprotein lipase (LPL) activity and 
inhibit fatty acid and TG synthesis, resulting in a decrease 
in serum VLDL and TG concentrations. The apolipoprotein 
C-III (apoC-III) particle, in contrast, inhibits LPL activity, 
resulting in diminished catabolism of  TG-containing par-
ticles such as VLDL.93,94 A null mutation in the gene encoding 
apoC-III has recently been discovered. Heterozygous carriers 
of this R19X mutation have been found to have lower serum 
TG, higher HDL-C, and lower coronary artery calcification 
and than noncarriers,95 suggesting impaired production of 
apoC-III may be beneficial. Fibric acid derivatives have 
been shown to inhibit apoC-III synthesis, thus enhancing 
LPL-mediated breakdown of TG-rich chylomicrons and 
VLDL and hepatic lipase-driven conversion of IDL to LDL. 
These actions indirectly increase HDL-C concentration fur-
ther due to increased uptake of surface-free cholesterol and 
phospholipid byproducts by HDL particles.93,96,97
Published data on fibric acid derivates are less robust in 
women than in male subjects. In the Veterans Affairs High-
Density Lipoprotein Cholesterol Intervention Trial (VA-HIT), 
a secondary prevention study conducted in men, treatment 
with gemfibrozil (1,200 mg/day) led to a 6% increase in 
HDL-C along with a 4% reduction in total cholesterol, 31% 
reduction in TG and no change in LDL-C relative to baseline. 
This conferred a 22% relative risk reduction in the composite 
endpoint of nonfatal myocardial infarction or CHD death.98 
Of all the measured lipid changes however, the increase in 
HDL-C was the only on-treatment alteration to significantly 
correlate with reduction in CHD risk.99 The Helsinki Heart 
Study, another landmark trial of gemfibrozil in male subjects, 
described similar improvement in cardiac endpoints after 
five years in a primary prevention population.100 An analysis 
of lipoprotein particle subclasses in VA-HIT demonstrated 
that gemfibrozil increased LDL particle size while lowering 
numbers of LDL particles and increased HDL particle 
number and small HDL subfractions out of proportion to 
overall increases in HDL-C levels.101 The authors speculated 
that such alterations in lipoprotein makeup may be beneficial 
and potentially contribute to the cardiovascular risk reduction 
observed with gemfibrozil therapy. As noted previously, 
however, the clinical significance of differences in HDL 
subclass distribution remains unclear.
The Fenofibrate Intervention and Event Lowering in 
Diabetes Study (FIELD) examined 9,795 type 2 diabetics, 
3,657 of whom were women, in a predominantly primary 
prevention setting. It depicted only small increases in 
HDL-C with fenofibrate therapy. At four months of treatment, 
fenofibrate use (200 mg/day) was associated with a 5% 
increase in HDL-C. The effect decreased to 2% at the end 
of five years of treatment, though this decrement is likely 
confounded by a disproportionately high drop-in rate of lipid 
modifying therapy, predominantly statins, in the placebo 
group compared to the treatment group (36% vs 19%).102 
Further published data are required to determine any 
gender-related differences in HDL-C modification and 
cardiovascular outcomes in response to fibrate therapy.
Niacin
Nicotinic acid (niacin), a water-soluble B vitamin, is the 
single most effective pharmacologic agent currently available 
for raising HDL-C.103 Therapy with niacin results in a 
15%–35% increase in HDL-C, with the highest increases 
reported with doses of 1–2 g daily.104 Niacin additionally 
provides significant decreases in LDL-C and TG levels,105 
and up to a 39% reduction in lipoprotein(a) levels.106,107 
Niacin also appears to affect lipoprotein subclass distribution 
favorably. Observed is a decrease in small, dense atherogenic 
LDL particles and an increase in large, buoyant HDL particles 
comprising the HDL2 subfraction, without a net effect on 
small HDL particles.12 A meta-analysis of trials of extended-
release niacin in men and women demonstrated similar effects 
on HDL-C by gender, and statistically significant more 
favorable effects on LDL-C and TG in women compared 
to men.108 Major limitations to widespread use of niacin, 
however, include the high prevalence of intolerance due to 
flushing and smaller adverse effects on glucose metabolism, 
though extended-release formulations appear to be more 
tolerable from with regard to flushing.104,106,107
Combination therapy of niacin with other agents has 
been shown to provide greater increases in HDL-C in trials 
involving women and men. When statins and fibrates are International Journal of Women’s Health 2009:1 187
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used together, a 22% increase in HDL-C has been described. 
Similarly, the combination of statins and niacin may produce 
a 27% improvement in HDL-C.109,110 Such combined 
drug regimens have been shown to induce regression of 
atherosclerotic coronary plaques in women.109–111
Estrogen
Estrogen replacement therapy has been shown to have a 
favorable effect on lipid and lipoprotein levels. HDL-C 
increases of up to 15% and an LDL-C decrease of 15% 
can be expected with use of oral estrogen.112,113 However, 
despite this apparently beneficial effect on serum lipids, 
estrogen replacement therapy has demonstrated no benefit 
in reducing coronary outcomes in postmenopausal women. 
The Heart and Estrogen/Progestin Replacement Study 
(HERS) showed a statistically significant 52% increase in the 
risk of cardiac death or nonfatal MI during the first year of 
follow-up in postmenopausal women treated with combined 
estrogen plus progestin. A similar early increase in risk of 
pulmonary embolism and coronary events was observed 
during the first 3 years of the Women’s Health Initiative 
(WHI).114,115 Although these findings may be slightly offset 
by the inclusion of older women who lacked menopausal 
symptoms, current recommendations do not support the use 
of estrogen replacement therapy to reduce cardiovascular risk 
in postmenopausal women.
Emerging therapies
In light of the recent discovery of the R19X null mutation for 
the apoC-III gene and its apparent cardioprotective effects, 
treatments targeted specifically toward downregulation of 
apoC-III may soon be examined. Promising new therapies 
to raise HDL-C that are already being investigated include 
CETP inhibitors, exogenous HDL mimetics, and ABCA1 
upregulators. Given the emerging nature of these therapies, 
however, little gender-specific data currently exist.
Among the CETP inhibitors currently under investigation 
are JTT-705 and anacetrapib. In small pre-marketing trials 
using healthy men and women with mild dyslipidemia, 
JTT-705 has been shown to increase HDL-C by 34% and 
decrease LDL-C by 7%. The compound demonstrated no 
significant toxicity and was effective at increasing both 
HDL2 and HDL3 subfractions.116 Torcetrapib, the first CETP 
inhibitor studied, demonstrated dramatic increases in HDL-C 
when combined with atorvastatin compared to atorvastatin 
alone in a large-scale clinical trial involving 15,067 male 
and female subjects deemed to be at high cardiac risk.117 
The addition of torcetrapib to atorvastatin conferred a 72.1% 
increase in HDL-C and 24.9% decrease in LDL-C following 
12 months of therapy. The trial was ultimately terminated, 
however, due to increased morbidity and mortality in the 
experimental arm. In particular, the addition of torcetrapib 
was associated with increased risk for cardiovascular 
events (hazard ratio, 1.25; 95% CI: 1.09–1.44; P = 0.001), 
as well as death from any cause (hazard ratio, 1.58; 95% 
CI: 1.14–2.19; P = 0.006). There were more deaths from 
cardiovascular causes (49 vs 35) as well as noncardiovascular 
causes (40 vs 20) in the experimental arm. Also seen in the 
torcetrapib group were increases in blood pressure (5.4 mmHg 
systolic and 2.0 mmHg diastolic), decreases in potassium con-
centration, and increases in sodium and bicarbonate levels. 
Consequently, mineralocorticoid excess has been proposed as 
a potential mechanism of torcetrapib-induced cardiovascular 
harm, and this theory has been supported by the post hoc 
observation of increased serum aldosterone concentrations 
in torcetrapib-treated patients. An alternate suggested 
explanation for the observed adverse cardiovascular outcomes 
in the torcetrapib group involves the supposition that CETP 
inhibition may actually produce HDL particles that are less 
functional or potentially harmful.117 Similar deleterious 
effects on outcomes or blood pressure have not yet been 
reported in smaller-scale trials of anacetrapib, another CETP 
inhibitor under investigation, which has shown up to a 40% 
reduction in LDL-C and 139% increase in HDL-C compared 
to placebo, and incremental effects on LDL when combined 
with atorvastatin.118 Further study is required to determine 
whether CETP inhibition is an effective and safe strategy to 
halt atherosclerosis and reduce cardiovascular events.
ApoA-I Milano, a naturally occurring variant of apo A-I, 
is found in individuals with very low levels of HDL-C but no 
overt signs of atherosclerosis.119 Intravenous administration 
of a recombinant form of apoA-I Milano was recently 
examined in patients with recent acute coronary syndrome 
events. As assessed by intravascular ultrasound, significant 
coronary atheroma regression was seen in patients receiving 
intravenous infusions of recombinant apoA-I Milano, while 
those receiving placebo experienced plaque progression.120 
In animal studies, the recombinant compound facilitates the 
formation of large HDL particles, which appear to be more 
active in reverse cholesterol transport.121 Gene therapy with 
apoA-I Milano is currently being investigated in the murine 
model and may represent a promising new approach to 
reducing atherosclerosis.122
Another trial of infusion therapy involved CSL-111, 
a reconstituted HDL (rHDL) constructed from human 
apoA-I combined with soybean-derived phosphatidylcholine. International Journal of Women’s Health 2009:1 188
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(ERASE) study found that four weekly infusions of reconstituted 
HDL failed to significantly change coronary atheroma volume 
as assessed by IVUS compared to placebo, though investigators 
did report statistically significant improvements in the 
plaque characterization index on IVUS and coronary score 
on quantitative coronary angiography. Additionally, patients 
randomized to receive a higher dose of CSL-111 experienced 
elevations in aminotransferase levels, prompting premature 
discontinuation in the high dose group.123
Patients with Tangier disease and familial HDL deficiency 
have mutations in the ABCA1, resulting in severely 
diminished concentrations of HDL-C. Thus, upregulation 
of the ABCA1 transporter may represent a new therapeutic 
model for increasing HDL-C levels. ABC transporters 
are expressed in macrophages and are thought to mediate 
cholesterol efflux from macrophage foam cells into the major 
HDL fractions.124 This might explain the inverse relationship 
between HDL-C levels and atherosclerosis risk. Drugs that 
induce ABCA1 in mice increase clearance of cholesterol 
from tissues and inhibit intestinal absorption of dietary 
cholesterol.125 More translational research on the effects of 
ABCA1 in humans is needed to delineate the benefits that 
ABCA1-targeted compounds may provide.
Conclusion
Baseline HDL-C levels are inextricably linked to cardiovascular 
outcomes in women and men. Many new and effective strate-
gies exist to raise HDL-C in women. Among drug therapies, 
niacin continues to be the most effective, especially when 
combined with fibrate or statin therapy. Currently, no role 
exists for the use of estrogen replacement therapy to raise 
HDL-C or to reduce cardiovascular risk in postmenopausal 
women. Lifestyle alterations that include dietary changes, 
smoking cessation and aerobic exercise must be employed 
concomitantly with pharmacotherapy to achieve the best 
clinical results. New modalities currently being investigated 
to further increase HDL-C levels include CETP inhibitors, 
exogenous HDL mimetics, and ABCA1 upregulators.
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